Click a link below to view the mailing archive as if it had been sent to you.
2016-09-30 12:15 | | 2 patients dead, Boehringer scraps plans for high-speed development, kills $730M Hanmi deal and more... |
2016-09-29 12:15 | | FDA approves Medtronic's 'artificial pancreas' for diabetes and more... |
2016-09-28 12:15 | | Which drugmakers have the healthiest presence on social media? and more... |
2016-09-28 00:15 | | From FDA expert to biotech insider: The drug industry thrives on the revolving door and more... |
2016-09-27 12:15 | | Sanofi grabs $43M in U.S. government funds to advance Zika vaccine into Phase II and more... |
2016-09-27 00:15 | | J&J Finally Returning to Its Roots in Diversity? and more... |
2016-09-26 12:15 | | Pfizer Decides Not to Split, Ending Years of Speculation and more... |
2016-09-25 12:15 | | As Clinton-Trump Debate Looms, It's Drug Prices, Not Obamacare, Taking Stage and more... |
2016-09-25 00:15 | | Saluting Biotech M&A: Onward And Upward and more... |
2016-09-24 00:15 | | FDA approves Amgen's copy of AbbVie arthritis drug Humira and more... |
2016-09-23 12:15 | | Valeant backlash continues: De Silva out at Endo and more... |
2016-09-23 00:15 | | Secret trove reveals bold ‘crusade’ to make OxyContin a blockbuster and more... |
2016-09-22 12:15 | | Teva, Perrigo and Sun join list of suitors checking out Bayer's $1.1B derm unit and more... |
2016-09-22 00:15 | | Novartis continues data push for Entresto and more... |
2016-09-21 12:15 | | Zombie biotech Eleven Bio seeks resurrection with merger deal and more... |
2016-09-21 00:15 | | Ariad Shares Rise Amid Speculation of Potential Buyout and more... |
2016-09-20 12:15 | | A silver lining to the drug-pricing uproar? For generic competition, yes, GPhA chief says and more... |
2016-09-20 00:15 | | Valeant: rebates on heart drugs are coming and more... |
2016-09-19 12:15 | | FDA approves Sarepta’s controversial drug for Duchenne muscular dystrophy and more... |
2016-09-18 12:15 | | Roche To Topple Novartis As Industry's Biggest Seller and more... |
2016-09-18 00:15 | | Novartis shows a hole card in a high-stakes PhIII poker game for MS drugs and more... |
2016-09-17 00:15 | | Abbott to sell its eye care business to J&J for about $4.33 bln |
2016-09-16 12:15 | | One Company's Employees Say an Acquisition Was Mishandled and more... |
2016-09-16 00:15 | | Bayer's $66B Monsanto buy spells bad news for its pharma ambitions: Analysts and more... |
2016-09-15 12:15 | | FDA panel votes to remove serious warning from Pfizer’s smoking cessation pill and more... |
2016-09-15 00:15 | | Key FDA Decisions and Trial Results Coming in the Next 2 Months and more... |
2016-09-14 12:15 | | Allergan to acquire Vitae Pharma in an all-cash deal valued at about $639 million and more... |
2016-09-14 00:15 | | All that pharmaceutical advertising may be a ‘mixed bag,’ after all and more... |
2016-09-13 12:15 | | Gilead Sciences, Inc. Can Fancy TESARO Inc for Acquisition and more... |
2016-09-13 00:15 | | GSK continues sell-off of non-core assets and more... |
2016-09-12 12:15 | | Horizon Buys Rare-Disease Company Raptor for $800 Million and more... |
2016-09-12 00:15 | | 4 Key BioPharma Movers in the Past Week and more... |
2016-09-10 12:15 | | Pharma plays the blame game at the top and more... |
2016-09-10 00:15 | | Organovo launches bio-printed kidney tissue service and more... |
2016-09-09 12:15 | | Bayer eyes $1B-plus dermatology sale to fund Monsanto quest and more... |
2016-09-09 00:15 | | Pfizer CEO says Clinton plan to curb drug prices would hurt consumers and more... |
2016-09-08 12:15 | | Express Scripts targets inflammatory diseases for latest cost control program and more... |
2016-09-08 00:15 | | BioMarin hits snag with latest rare disease drug and more... |
2016-09-07 12:15 | | The EpiPen Debacle Coupled With Theranos And Turing: Is This Industry Broken? and more... |
2016-09-07 00:15 | | Mylan faces two potential class action lawsuits over EpiPen pricing and more... |
2016-09-06 12:15 | | Novo Nordisk faces delay for insulin combo and more... |
2016-09-05 12:15 | | Arena to focus on R&D with new spinout and old candidates and more... |
2016-09-04 12:15 | | Think EpiPen is Mylan's first scandal? Here's a timeline of jet use, an unearned MBA and more and more... |
2016-09-04 00:15 | | 8 Major FDA Decisions and Trial Results to Watch for in September and more... |
2016-09-03 00:15 | | J&J Wins Dismissal of Two New Jersey Talc Cancer Lawsuits and more... |
2016-09-02 12:15 | | Third U.S. patent on Teva's MS drug Copaxone invalidated and more... |
2016-09-02 00:15 | | Takeda Pharmaceuticals enters race for a Zika vaccine and more... |
2016-09-01 12:15 | | Report: 3 tips for pharma to provide beyond-the-pill services and more... |
2016-09-01 00:15 | | How Mylan tried to keep Teva from selling a generic EpiPen and more... |